Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options

Cancer Treatment Reviews

Volumn 37, Issue 3, 2011, Pages 169-177

  Faloppi, Luca ^a   Scartozzi, Mario ^a   Maccaroni, Elena ^a   Di Pietro Paolo, Marzia ^b   Berardi, Rossana ^a   Del Prete, Michela ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Ospedale 'Profili'   (Italy)

Author keywords

HBx; Hepatocellular carcinoma; Molecularly targeted therapy; Sorafenib; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; DOXORUBICIN; ERLOTINIB; GEFITINIB; LAPATINIB; PLACEBO; SORAFENIB; SUNITINIB; VANDETANIB; VATALANIB;

ALCOHOL CONSUMPTION; ANOREXIA; ARTIFICIAL EMBOLISM; ASTHENIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOEMBOLIZATION; CRYOABLATION; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HAND FOOT SYNDROME; HEPATITIS VIRUS; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEINURIA; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR ABLATION; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DRUG DELIVERY SYSTEMS; HUMANS; INDOLES; LIVER NEOPLASMS; PYRIDINES; PYRROLES;

EID: 79952008530     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.08.001     Document Type: Review

References (96)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. Ca Cancer J Clin 2005, 55:74-108.
2. Montalto G., Cervello M., Giannitrapani L., et al. Epidemiology, risk factors and natural history of hepatocellular carcinoma. Ann NY Acad Sci 2002, 963:13-20.
3. Gomaa A.I., Khan S.A., Toledano M.B., et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008, 14(27):4300-4308.
4. La Vecchia C., Negri E., Pelucchi C. The rise and fall in primary liver cancer mortality in Italy. Digestive Liver Dis 2002, 34:169-171.
5. Bosch F.X., Ribes J., Diaz M., Claries R., et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
6. El-Serag H.B. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007, 37(Suppl. 2):S88-S94.
7. Parikh S., Hyman D. Hepatocellular cancer: a guide for the internist. Am J Med 2007, 120:194-202.
8. Suruky R.J., Mueller N., Hayashi K., et al. Host immune status and incidence of hepatocellular carcinoma among subject infected with hepatitis C virus: a nested case-control study in Japan. Cancer Epidemiol Biomarkers Prev 2006, 15:2521-2525.
9. Liu C.J., Kao J.H. Hepatitis B virus related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chin Med Assoc 2007, 70:141-145.
10. McKillop I.H., Schrum L.W. Alcohol and liver cancer. Alcohol 2005, 35:195-203.
11. Voigt M.D. Alcohol in hepatocellular cancer. Clin Liver Dis 2005, 9:151-169.
12. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenetic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
13. Chun G., Shu-Kun Y. Diabetes mellitus: a " true" independent risk factor for hepatocellular carcinoma?. Hepatobiliary Pancreat Dis Int 2009, 8:465-473.
14. Rossi M., Lipworth L., Dal Maso L., et al. Dietary glycemic load and hepatocellular carcinoma with or without chronic hepatitis infection. Ann Oncol 2009, 20(10):1736-1740.
15. Theise N.D., Park Y.N., Kojiro M. Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 2002, 6:497-512.
16. Borzio M., Fargion S., Borzio F., et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003, 39:208-214.
17. Park Y.N., Chae K.J., Kim Y.B., Park C., Theise N. Apoptosis and proliferation in hepatocarcinogenesis related to cirrhosis. Cancer 2001, 92:2733-2738.
18. Nakashima Y., Nakashima O., Tanaka M., et al. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res 2003, 26:142-147.
19. Roskams T.A., Libbrecht L., Desmet V.J. Progenitor cells in diseased human liver. Semin Liver Dis 2003, 23:385-396.
20. Sell S. Cellular origin of hepatocellular carcinomas. Semin Cell Dev Biol 2002, 13:419-424.
21. Waris G., Siddiqui A. Regulatory mechanisms of viral hepatitis B and C. J Biosci 2003, 28:311-321.
22. Tellinghuisen T.L., Rice C.M. Interaction between hepatitis C virus protein and host cell factors. Curr Opin Microbiol 2002, 5:419-427.
23. Block T.M., Mehta A.S., Fimmel C.J., et al. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003, 22:5093-5107.
24. Giambartolomei S., Covone F., Levrero M., et al. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein. Oncogene 2001, 20:2606-2610.
25. Sun A., Ingelman-Sundberg M., Neve E., et al. Ethanol and oxidative stress. Alcohol Clin Exp Res 2001, 25(5 Suppl. ISBRA):237S-243S.
26. Lu S.C. Regulation of glutathione synthesis. Cur Top Cell Regul 2000, 36:95-116.
27. Diehl A.M. Recent events in alcoholic liver disease. V. Effects of ethanol on liver regeneration. Am J Physiol Gastrointest Liver Physiol 2005, 288:G1-G6.
28. Llovet J.M. Update treatment approach to hepatocellular carcinoma. J Gastroenterol 2005, 40:225-235.
29. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with and-stage liver disease. Hepatology 2001, 33:464-470.
30. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
31. Llovet J.M., Bustamante J., Castells A., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999, 29:62-67.
32. Vauthey J., Lauwers G., Esnaola N., et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002, 20:1527-1536.
33. Greene F.L. AJCC cancer staging manual 2002, Springer, New York. 6th ed.
34. Okuda K., Ohtsui T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56:918-928.
35. Leung T.W., Tang A.M., Zee B., et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002, 94:1760-1769.
36. CLIP Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000, 31:840-845.
37. Chevret S., Trinchet J.C., Mathieu D., et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999, 31:133-141.
38. Kudo M., Chung H., Haji S., et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004, 40:1396-1405.
39. Nanashima A., Sumida Y., Abo T., et al. Modified Japan integrated staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol 2006, 41:250-256.
40. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
41. Kamath P.S., Kim W.R. The model for end-stage liver disease (MELD). Hepatology 2007, 45:797-805.
42. Bruix J., Sherman M. Management of hepatocellular carcinoma. AASLD practice guideline. Hepatology 2005, 42:1208-1236.
43. Llovet J.M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: review of the randomized clinical trials. Lancet Oncol 2002, 3:593-603.
44. Lencioni R., Allagaier H.P., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: randomized controlled trial of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 2003, 228:235-240.
45. Lin S., Lin C., Lin C., et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4cm or less. Gastroenterology 2004, 127:1714-1723.
46. Okada S. Chemotherapy in hepatocellular carcinoma. Hepatogastroenterology 1998, 45(Suppl. 3):1259-1263.
47. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:4293-4300.
48. Llovet J., Ricci S., Mazzaferro V., et al. SHARP investigators. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial. J Clin Oncol 2007, LBA1.
49. Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
50. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
51. Chang Y.S., Adnane J., Trail P.A., et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007, 59:561-574.
52. Villanueva A., Newell P., Chiang D.Y., et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27:55-76.
53. Calvisi D.F., Ladu S., Gorden A., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130:1117-1128.
54. Semela D., Dufour J.F. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004, 41:864-880.
55. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
56. Liu L., Cao Y., Chen C., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66:11851-11858.
57. Cheng A., Kang Y., Chen Z., et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 2008, U26:4509.
58. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597-3605.
59. Zhu A.X., Sahani D.V., di Tomaso E., et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2007, 25:4637.
60. Faivre S.J., Raymond E., Douillard J., et al. Assessment of safety and drug induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2007, 25:3546.
61. Zhu A.X., Stuart K., Blaszkowsky L.S., et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007, 110:581-589.
62. Gruenwald V., Wilkens L., Gebel M. A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. J Clin Oncol 2007, 25:A4594.
63. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005, 23:6657-6663.
64. Thomas M.B., Chadha R., Glover K., et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007, 110:1059-1067.
65. O'Dwyer P.J., Giantonio B.J., Levy D.E., et al. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol 2006, 24:4143.
66. Ramanathan R.K., Belani C.P., Singh D.A., et al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. J Clin Oncol (Meeting Abstracts) 2006, 24(18S). [Abstract 4010].
67. Chao Y., Li C.P., Chau G.Y., et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003, 55-62.
68. Poon R.T., Ho J.W., Tong C.S., et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004, 91:1354-1360.
69. Siegel A.B., Cohen E.I., Ocean A., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008, 26:2992-2998.
70. Thomas M.B., Chadha R., Iwasaki M., et al. The combination of bevacizumab and erlotinib shows significant biological activity in patients with advanced hepatocellular carcinoma. J Clin Oncol 2007, 25:4567.
71. Schwartz J., Schwartz M., Lehrer D. Bevacizumab in unresectable hepatocellular carcinoma for patients without metastasis and without invasion of the portal vein. J Clin Oncol 2006, 24:A4144.
72. Zhu A.X., Blaszkowsky L.S., Ryan D.P., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:1898-1903.
73. Koch I., Baron A., Roberts S. Influence of hepatic dysfunction on safety, tolerability and pharmacokinetics of PTK787/ZK222584 in patients with unresectable HCC. J Clin Oncol 2005, 23:A4134.
74. Alberts SR, Morlan BW, Kim GP, et al. NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)-interim review of toxicity. In: 2007 Gastrointestinal cancer symposium, Orlando, FL, January 19-21, 2007 [Abstract 186].
75. Sahin F., Kannangai R., Adegbola O., et al. MTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004, 10:8421-8425.
76. Ribatti D., Nico B., Mangieri D., et al. In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin. Histol Histopathol 2007, 22:285-289.
77. Sieghart W., Fuereder T., Schmid K., et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007, 83:425-432.
78. Available at: http://www.cancer.gov/clinicaltrials/search.
79. Nanashima A., Yano H., Yamaguchi H., et al. Immunohistochemical analysis of tumor biological factors in hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection. J Gastroenterol 2004, 39(2):148-154.
80. Ouchi K., Sugawara T., Ono H., et al. Mitotic index is the best predictive factor for survival of patients with resected hepatocellular carcinoma. Dig Surg 2000, 17:42-48.
81. Watanabe J., Kushihata F., Honda K., et al. Prognostic significance of Bcl-xLIto in human hepatocellular carcinoma. Surgery 2004, 135(6):604-612.
82. Fields A.C., Cotsonis G., Sexton D., et al. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol 2004, 17:1378-1385.
83. Ikeguci M., Ueta T., Yamane Y., et al. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin Cancer Res 2002, 8(10):3131-3136.
84. O'Connor D.S., Schechner J.S., Adida C., et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000, 156:393-398.
85. Kobayashi T., Kubota K., Takayama T., et al. Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg 2001, 181:284-288.
86. Ohashi R., Gao C., Miyazaki M., et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res 2001, 21:657-662.
87. Fiorentino M., Altimari A., D'Errico A., et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 2000, 6:3966-3972.
88. Xu X., Yamamoto H., Sakon M., et al. Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin Cancer Res 2003, 9(5):1764-1772.
89. Qin L.X., Tang Z.Y., Ma Z.C., et al. P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol 2002, 8(3):459-463.
90. Matsumura T., Makino R., Mitamura K. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res 2001, 7:594-599.
91. Inagawa S., Itabashi M., Adachi S., et al. Expression and prognostic roles of β-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002, 8:450-456.
92. Endo K., Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 2000, 32:78-84.
93. Ito Y., Takeda T., Sakon M., et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001, 84:1377-1383.
94. Altimari A., Fiorentino M., Gabusi E., et al. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis 2003, 35:332-338.
95. Giannelli G., Bergamini C., Marinosci F., et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002, 97:425-431.
96. Zheng Q., Tang Z.Y., Xue Q., et al. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 2000, 126:641-646.